Outlook Therapeutics, Inc. (OTLK)
CIK 1649989 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 120.9M shares as of May 12, 2026 (10-Q). Share count fell from 260.3M to 23.4M between Feb 12, 2024 and May 13, 2024, a pattern consistent with a reverse split (roughly 1-for-11); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Twenty Five March Two Thousand Thirty One One | 20.0M | $0.25 | — | — |
| Twenty Seventh May Two Thousand Thirty | 15.3M | $1.4 | — | — |
| Seventeen January Two Thousand Thirty | 13.2M | $2.26 | — | — |
| Eighteen March Two Thousand Twenty Nine | 5.8M | $7.7 | — | — |
| Placement Agent Warrants | 1.4M | $0.3125 | 5y | — |
| Twenty Five March Two Thousand Thirty One Two | 1.4M | $0.3125 | — | — |
| Fifteenth April Two Thousand Twenty Nine | 1.1M | $7.7 | — | — |
| Twenty Third November Two Thousand Twenty Six | 104,999 | $31.25 | — | — |
| Investor Warrants | not tagged | $0.25 | 5y | — |
| Class of Warrant or Right Warrants Existing Prior To2025 | not tagged | $2.26 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed May 15, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 45.3M underlying shares, as reported Dec 31, 2018 (10-Q).
Reported exercise price: $7.7 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $722,229 as of Mar 31, 2026.
Rough fully diluted estimate: 166.2M = 120.9M O/S + 45.3M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Unsecured Convertible Promissory Note March 2025 | $33.1M | — | $2.26 | — | ~14.6M sh |
If every note above converted at its tagged price: ~14.6M new shares on 120.9M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed May 15, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 120.9M | May 12, 2026 |
| + Twenty Five March Two Thousand Thirty One One (if exercised) | 20.0M | Mar 31, 2026 |
| + Twenty Seventh May Two Thousand Thirty (if exercised) | 15.3M | Mar 31, 2026 |
| + Seventeen January Two Thousand Thirty (if exercised) | 13.2M | Mar 31, 2026 |
| + Eighteen March Two Thousand Twenty Nine (if exercised) | 5.8M | Mar 31, 2026 |
| + Placement Agent Warrants (if exercised) | 1.4M | Mar 25, 2026 |
| + Twenty Five March Two Thousand Thirty One Two (if exercised) | 1.4M | Mar 31, 2026 |
| + Fifteenth April Two Thousand Twenty Nine (if exercised) | 1.1M | Mar 31, 2026 |
| + Twenty Third November Two Thousand Twenty Six (if exercised) | 104,999 | Mar 31, 2026 |
| + Unsecured Convertible Promissory Note March 2025 (if fully converted) | 14.6M | Mar 13, 2025 |
| Fully diluted estimate | 193.7M | +60.3% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $27.1Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 8 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full OTLK workspace